These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 4984418)

  • 1. [Antimycobacterial activity of rifomycin in vitro in various media].
    Hennebert A
    Acta Tuberc Pneumol Belg; 1969; 60(3):348-55. PubMed ID: 4984418
    [No Abstract]   [Full Text] [Related]  

  • 2. [Experimental research on the antimycobacterial activity of rifampicine: 3-(4-methyl-l-piperazinyl-iminomethyl)-rifomycin SV].
    Lucchesi M; Mancini P; Zubiani M
    Ann Ist Carlo Forlanini; 1967; 27(2):119-36. PubMed ID: 4973676
    [No Abstract]   [Full Text] [Related]  

  • 3. The antimycobacterial activity of rifampicin "in vitro".
    Zierski M; Wozniak S; Tomaszkiewicz L
    Acta Tuberc Pneumol Belg; 1969; 60(3):341-7. PubMed ID: 4984417
    [No Abstract]   [Full Text] [Related]  

  • 4. [Experimental studies of the antimycobacterial activity of Rifampicine].
    Nitti V; Catena E; Ninni A; Di Filippo A
    Arch Tisiol Mal Appar Respir; 1966 Nov; 21(11):867-910. PubMed ID: 4969274
    [No Abstract]   [Full Text] [Related]  

  • 5. [Experimental aspects of the antimycobacterial activity of rifampicin].
    Blasi A; Di Perna A; Vinciguerra E
    Arch Tisiol Mal Appar Respir; 1967 Nov; 22(11):943-66. PubMed ID: 4978601
    [No Abstract]   [Full Text] [Related]  

  • 6. [Antimycobacterial activity of rifomycin: in vitro and in vivo studies].
    Tacquet A; Devulder B; Martin JC; Daniel H; Le Bouffant L
    Acta Tuberc Pneumol Belg; 1969; 60(3):366-89. PubMed ID: 5371669
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv.
    Ahmad Z; Sharma S; Khuller GK
    FEMS Microbiol Lett; 2005 Oct; 251(1):19-22. PubMed ID: 16143463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rifomycin in treatment of tuberculosis with polyresistant mycobacteria: clinical and laboratory observations].
    Daddi G; Lucchesi M
    Acta Tuberc Pneumol Belg; 1969; 60(3):442-9. PubMed ID: 4984423
    [No Abstract]   [Full Text] [Related]  

  • 9. [In vitro study on cross resistance of rifampin and rifapentine for Mycobacterium tuberculosis].
    Duanmu HJ; Liu YH; Jiang GL; Wang SM; Fu YH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Mar; 28(3):192-4. PubMed ID: 15854417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Growth of rifampin-dependent Mycobacterium tuberculosis in conditions without rifampin].
    Zhong M; Wang Y; Sun C; Yin H; Wang A; Zhong M; Lou L
    Zhonghua Jie He He Hu Xi Za Zhi; 2002 Oct; 25(10):588-90. PubMed ID: 12490123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of rifampicin action on mycobacterial cells. Consideration to the potentiation problem of antimycobacterial treatment.
    Trnka L
    Acta Tuberc Pneumol Belg; 1969; 60(3):356-65. PubMed ID: 4984419
    [No Abstract]   [Full Text] [Related]  

  • 12. [Conditions for rifampicin activity and the formation of resistant Mycobacterium tuberculosis in in vitro experiments].
    Dolzhanskiĭ VM
    Probl Tuberk; 1982 Mar; (3):59-62. PubMed ID: 6806807
    [No Abstract]   [Full Text] [Related]  

  • 13. [An investigation on multiple drug resistance of the rifampin resistant strains of Mycobacterium tuberculosis].
    Kuang T; Jin G; Song P; Li W; Wang Z
    Wei Sheng Wu Xue Bao; 1998 Apr; 38(2):152-4. PubMed ID: 12549378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of an intracellular pharmacokinetic in vitro infection model as a tool to assess tuberculosis therapy.
    Cappelletty DM
    Int J Antimicrob Agents; 2007 Feb; 29(2):212-6. PubMed ID: 17204402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative study of the development of rifomycin blood levels in humans by 2 different microbiologic methods].
    Canetti G; Djurovic V; Le Lirzin M; Thibier R; Lepeuple A
    Rev Tuberc Pneumol (Paris); 1970; 34(1):93-106. PubMed ID: 4996249
    [No Abstract]   [Full Text] [Related]  

  • 16. [Resistance of Mycobacterium tuberculosis strains to antimycobacterial preparations].
    Iavors'ka HV; Puhachevs'ka LP
    Mikrobiol Z; 2006; 68(5):44-51. PubMed ID: 17388119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of rifampicin and isoniazid resistances of Mycobacterium tuberculosis strains by particle counting immunoassay (PACIA).
    Drowart A; Cambiaso CL; Huygen K; Serruys E; Portaels F; Jann E; Van Vooren JP
    Int J Tuberc Lung Dis; 1997 Jun; 1(3):284-8. PubMed ID: 9432378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Facile one-pot synthesis and antimycobacterial evaluation of pyrazolo[3,4-d]pyrimidines.
    Trivedi A; Dodiya D; Surani J; Jarsania S; Mathukiya H; Ravat N; Shah V
    Arch Pharm (Weinheim); 2008 Jul; 341(7):435-9. PubMed ID: 18574851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.
    Bhusal Y; Shiohira CM; Yamane N
    Int J Antimicrob Agents; 2005 Oct; 26(4):292-7. PubMed ID: 16150578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The "in vitro" activity of rifampicin compared with ethambutol, capreomycin and isoniazid.
    Steinbrück PW
    Acta Tuberc Pneumol Belg; 1969; 60(3):413-6. PubMed ID: 4984421
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.